Concorde Financial’s Amgen AMGN Stock Holding History

Concorde Financial’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-306	Closed	-$70K	–	65
2021 Q4	$70K	Buy	+306	New	+$64.6K	0.04%	46

Other funds holding AMGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Concorde Financial's AMGN Position: Q1 2022 in Review

Concorde Financial sold out of Amgen (AMGN) in Q1 2022, closing a stake of 306 shares — an estimated $70K sold.

Concorde Financial first reported a position in AMGN in Q4 2021 and held it in 1 quarter. The position peaked at $70K in Q4 2021. 2,338 funds tracked by Wall St. Rank hold AMGN as of Q1 2022.

Concorde Financial reported no remaining Amgen position as of Q1 2022 after selling out during the quarter.
Concorde Financial sold 306 Amgen shares in Q1 2022, an estimated $70K.
Concorde Financial first reported a position in Amgen in Q4 2021 and held it in 1 quarter.
Concorde Financial's Amgen position peaked at $70K in Q4 2021.
2,338 funds tracked by Wall St. Rank held Amgen as of Q1 2022.

Based on Concorde Financial's 13F filing for Q1 2022, filed 16 May 2022.